Orphazyme (0CUM) Stock Statistics & Valuation Metrics

Orphazyme has a market cap or net worth of kr37.61M. The enterprise value is kr26.44M.

Orphazyme has 54,112 shares outstanding. The number of shares has decreased by -2.65% in one year.

Orphazyme’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -13.30%.

The current PE Ratio of Orphazyme is 20.3. Orphazyme’s PEG ratio is ―.

In the last 12 months, Orphazyme had revenue of 309.00K and earned -859.00K in profits. Earnings per share was -21.00.

In the last 12 months, operating cash flow was 1.15M and capital expenditures 0.00, giving a free cash flow of 1.15M billion.

Orphazyme pays an annual dividend of kr0.285, resulting in a dividend yield of ―

Orphazyme upcoming earnings date is Sep 2, 2025, TBA (Confirmed).

Orphazyme as a current ratio of 13.90, with Debt / Equity ratio of 0.00%

In the past 12 months, Orphazyme has paid 0.00 in taxes.

Orphazyme EV to EBITDA ratio is -11.74, with an EV/FCF ratio of -13.45.

Orphazyme has kr16.53M in cash and marketable securities with ― in debt, giving a net cash position of kr16.53M billion.

Gross margin is 100.00%, with operating margin of -791.59%, and net profit margin of -277.99%.

The average price target for Orphazyme is ―, which is 11.43% higher than the current price. The consensus rating is ―